Prescription Drugs 2 Go

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

Conclusions:
: We conclude that celecoxib is a powerful tool to improve dendritic cell-based immunotherapy and is associated with a reduction in the numbers and suppressive function of MDSC. These data suggest that immunotherapy approaches benefit from simultaneously blocking cyclooxygenase-2 activity. (Source: BMC Cancer)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

Summary: The prostaglandin E2 EP1 receptor as well as the inflammatory enzyme cyclooxygenase-2 have been suggested as targets for disease modulation, improvement of therapeutic response, and restoration of pharmacosensitivity in epilepsies. Translational development of respective add-on approaches requires careful analysis of putative effects on ictogenesis.Therefore we evaluated the impact of the EP1 receptor antagonist SC-51089, the EP1 receptor agonist misoprostol and the COX-2 inhibitors celecoxib and NS-398 in the mouse amygdala kindling model of temporal lobe epilepsy.Neither celecoxib nor NS-398 affected the generation, spread and termination of seizure activity. Whereas …

NEW YORK – Trial is set for early 2012 in securities litigation stemming from Pfizer Inc.’s marketing of painkillers Bextra and celebrex, according to the pretrial schedule set in an Aug. 20 order by a U.S. magistrate judge in New York (In re Pfizer Inc. Securities Litigation, MDL No. 1688, No. 04-9866, S.D. N.Y.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Arthritis Drugs Legal News)

Cytosolic phospholipase A2 (cPLA2) is the rate-limiting enzyme responsible for the generation of prostaglandins (PGs), which are bioactive lipids that play critical roles in maintaining gastrointestinal (GI) homeostasis. There has been a long-standing association between administration of cyclooxygenase (COX) inhibitors and GI toxicity. GI injury is thought to be induced by suppressed production of GI-protective PGs as well as direct injury to enterocytes. The present study sought to determine how pan-suppression of PG production via a genetic deletion of cPLA2 impacts the susceptibility to COX inhibitor–induced GI injury. A panel …

Conclusion: These results suggest that IL-17A stimulates the expression of bone resorption-related inflammatory cytokines through an autocrine mechanism involving celecoxib-blocked PGs, mainly PGE2, in osteoblasts. (Source: Archives of Oral Biology)

Molecular Pharmaceutics, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Molecular Pharmaceutics)

(Source: Reactions)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Arunasree et al. have extended their observations on the pathophysiology underlying resistance to imatinib mesylate in chronic myeloid leukemia (CML) . In prior observations, they had associated an overexpression of cyclooxygenase 2 (COX-2) with such resistance created in a K562 line . In this model, celecoxib, a selective COX-2 inhibitor overcame imatinib resistance. Overexpression of MDR1 in leukemia cells has been noted in this context previously by this group and others . Kim et al. have investigated the impact of 16 single nucleotide polymorphisms (SNP) in genes potentially associated with …